Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 19/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 12/20 | 0.74 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.74 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.74 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585356 | 0.85 | CHRNA4 (1.00) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3339871 | 0.85 | CHRNA4 (0.74) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3335557 | 0.83 | CHRNA4 (0.71) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3335863 | 0.78 | CHRNA4 (0.84) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL584813 | 0.77 | CHRNA4 (0.63) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL585609 | 0.77 | CHRNA4 (0.63) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3339714 | 0.77 | CHRNA4 (0.82) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3331039 | 0.76 | CHRNA4 (0.72) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL585539 | 0.74 | CHRNA4 (1.00) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3335786 | 0.73 | CHRNA4 (0.68) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580434-B2 | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes | ATTENUA, INC. (US) | 2017-02-28 | — | — | US | claimed |
| US-20160039833-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CATALYST BIOSCIENCES, INC. | 2016-02-11 | — | — | US | claimed |
| US-20150080576-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT INC (US) | 2015-03-19 | — | — | US | claimed |
| US-8268860-B2 | Sub-type selective amides of diazabicycloalkanes | TARGACEPT, INC. (US) | 2012-09-18 | — | — | US | claimed |
| EP-2284171-B1 | Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types | TARGACEPT INC (US) | 2012-02-15 | — | — | EP | claimed |
| EP-2284171-A1 | Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types | Targacept, Inc. (US) | 2011-02-16 | — | — | EP | claimed |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | claimed |
| EP-2094703-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | Targacept, Inc. (US) | 2009-09-02 | — | — | EP | claimed |
| WO-2008057938-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| US-9580434-B2 | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes | ATTENUA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580434-B2 | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes | ATTENUA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580434-B2 | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes | ATTENUA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160039833-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CATALYST BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039833-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CATALYST BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100081683-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGCEPT INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081683-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGCEPT INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2008057938-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080576-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA4, CHRNA2, CHRNE | CHRNA4 1/4885CHRNB2 5/4885CHRNB4 6/4885 |
| US-20100081683-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA7, CHRNE, CHRNA2 | CHRNA4 5/4885CHRNB2 4/4885CHRNB4 9/4885 |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA4, CHRNA2, CHRNE | CHRNA4 1/4885CHRNB2 5/4885CHRNB4 6/4885 |
| US-20160039833-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA2, CHRNE, CHRNA7 | CHRNA4 4/4885CHRNB2 5/4885CHRNB4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.